May 26, 2022 News by Marisa Wexler, MS Lesions in 3 Brain Regions Can Help Distinguish MS From Like Disorders People with multiple sclerosis (MS) are more likely to have lesions in three regions of the brain ā the anterior temporal horn, periventricular region, and cerebellar hemisphere ā compared with people with other inflammatory brain diseases, a study reports. Looking for lesions in these parts of the brain may…
July 20, 2021 News by Forest Ray PhD Nerve Tissue Scarring May Explain MS Progression Nerve tissue scars associated with multiple sclerosis (MS) show marked differences from those of similar neurodegenerative disorders, according to a recent study. MS-associated inflammation causes brain and spinal cord lesions (nerve tissue scarring) that often are bigger and last longer than those of two other demyelinating diseases: myelin oligodendrocyte…
June 10, 2021 News by Aisha I Abdullah PhD Inflammatory Immune Cells Found in Active, But Not Chronic, Brain Lesions A class of immune cells called myeloid cells that express the inflammatory protein SIGLEC1 may be able to distinguish between active and chronic multiple sclerosis (MS) brain lesions, a study found. The study, āSIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood…
May 28, 2020 News by Joana Carvalho, PhD MS Diagnostic Criteria Should Be Changed to First Rule Out NMOSD, Study Says Diagnostic guidelines for multiple sclerosis (MS) should be amended to first rule out the presence of neuromyelitis optica spectrum disorder (NMOSD), a neurological inflammatory disease that also affects the brain and spinal cord, a study recommends. The study, āCan a Diagnosis of Multiple Sclerosis Be…
May 4, 2020 News by Marisa Wexler, MS Pain, Fatigue in MS and Neuromyelitis Optica Spectrum Compared in Study Pain appears to be more intense in people with neuromyelitis optica spectrum disorder (NMOSD) than those with multiple sclerosis (MS), while fatigue levels are comparable between the two disorders, a study reports. Its researchers also link certain types of central nervous system lesions to pain and fatigue in…
August 8, 2019 News by Jose Marques Lopes, PhD Specific Mutation and Amino Acid Change Linked to MS Risk in Study from Japan An amino acid change to phenylalanine, and a specific class I HLA gene variant are associated with greater risk forĀ multiple sclerosis (MS), according to a study in Japanese patients. Researchers also identified an HLA variant, or mutation, associated with neuromyelitis optica spectrum disorder (NMOSD), an autoimmune condition…
August 1, 2018 News by Diogo Pinto Pregnancy Worsens Symptoms in MS Patients, Study Finds Pregnancy, including successful delivery or miscarriage, worsensĀ symptoms of multiple sclerosis (MS), as well as onset of the disease, a retrospective study shows. Researchers found the same effect of pregnancy on neuromyelitis optica spectrum disorders (NMOSD), an inflammatory disorder of the central nervous system characterized by demyelination and damage of…
July 23, 2018 News by Iqra Mumal, MSc Hypertension More Common in MS Patients Than General Public, Study Reports People with multiple sclerosis are 48 percent more likely to have high blood pressure compared to the general population ā and to people with other demyelinating diseases, a new study reports. Its researchers also emphasize that hypertension is already linked to poorer outcomes in MS patients. The study, āCardiovascular…
August 30, 2016 News by Patricia Silva, PhD TG Therapeutics’ Potential Neuromyelitis Optica Treatment Named Orphan Drug by FDA TheĀ U.S. Food and Drug AdministrationĀ (FDA) has designated TG-1101Ā (ublituximab), aĀ glycoengineered anti-CD20 monoclonal antibody byĀ TG Therapeutics, anĀ orphan drugĀ to advance its development. The drug is a potentialĀ treatment for neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD), two relapsing-remitting autoimmune diseases with similarities to multiple sclerosis. Currently, there are…
November 30, 2015 News by Patricia Silva, PhD People with Relapsing NMOD Invited to Enter Phase 3 Study The National Multiple Sclerosis Society recently announced that a research team is recruiting 132 patients with a diagnosis of neuromyelitis optica spectrum disorders (NMOSD) for a Phase 3 clinical study comparing an experimental medicine with an inactive placebo. NMOSD is a rare disorder caused by immune system cells attacking…